DK2155866T3 - Modificerede phosphataser - Google Patents

Modificerede phosphataser

Info

Publication number
DK2155866T3
DK2155866T3 DK08741670.7T DK08741670T DK2155866T3 DK 2155866 T3 DK2155866 T3 DK 2155866T3 DK 08741670 T DK08741670 T DK 08741670T DK 2155866 T3 DK2155866 T3 DK 2155866T3
Authority
DK
Denmark
Prior art keywords
phosphatases
modified
genetically
modified phosphatases
relates
Prior art date
Application number
DK08741670.7T
Other languages
English (en)
Inventor
Luigi Johannes Cornelius Jonk
Willem Raaben
Marty Bernardus Fransiscus Wulferink
Markwin Paul Velders
Original Assignee
Am-Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Am-Pharma B V filed Critical Am-Pharma B V
Application granted granted Critical
Publication of DK2155866T3 publication Critical patent/DK2155866T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK08741670.7T 2007-04-27 2008-04-25 Modificerede phosphataser DK2155866T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92669507P 2007-04-27 2007-04-27
EP07107176A EP1985697A1 (en) 2007-04-27 2007-04-27 Modified phosphatases
PCT/NL2008/050249 WO2008133511A2 (en) 2007-04-27 2008-04-25 Modified phosphatases

Publications (1)

Publication Number Publication Date
DK2155866T3 true DK2155866T3 (da) 2018-01-29

Family

ID=38521703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08741670.7T DK2155866T3 (da) 2007-04-27 2008-04-25 Modificerede phosphataser

Country Status (13)

Country Link
US (3) US8557545B2 (da)
EP (4) EP1985697A1 (da)
JP (1) JP5320387B2 (da)
CN (1) CN101688193B (da)
AU (1) AU2008244716B2 (da)
CA (1) CA2685405C (da)
DK (1) DK2155866T3 (da)
ES (1) ES2656405T3 (da)
HU (1) HUE036318T2 (da)
NO (1) NO2155866T3 (da)
PL (1) PL2155866T3 (da)
SI (1) SI2155866T1 (da)
WO (1) WO2008133511A2 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
CN1917899B (zh) 2004-02-04 2013-04-17 塞浦西斯阿瓦药物集团 碱性磷酸酶对存在于粘膜屏障的脂多糖解毒的用途
HUE039448T2 (hu) 2004-04-21 2018-12-28 Alexion Pharma Inc Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
WO2012169892A2 (en) * 2011-06-08 2012-12-13 Am-Pharma B.V. The use of alkaline phosphatase for preserving renal function
PT2814331T (pt) * 2012-02-16 2019-02-12 Elanco Us Inc Métodos e composições para redução do impacto ambiental de resíduos animais
WO2014031897A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral dosage forms having a high loading of (n,n- diethylcarbamoyl)methyl methyl|(2e)but-2-ene-1,4-dioate
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
CN103656637B (zh) * 2013-11-05 2015-02-25 范列英 抗人葡萄糖-6-磷酸异构酶单克隆抗体的用途
DK3097188T3 (da) 2014-01-24 2018-10-08 Am Pharma Bv Nedstrømsforarbejdning af en alkalisk phosphatase
US9926544B2 (en) 2014-01-24 2018-03-27 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
KR102644116B1 (ko) * 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 알칼린 포스파타제의 제조
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
JP6732368B2 (ja) * 2016-01-12 2020-07-29 東ソー株式会社 アルカリホスファターゼ及びその製造方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017173413A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CA3057089A1 (en) * 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2018198935A1 (ja) 2017-04-27 2018-11-01 日本板硝子株式会社 低反射コーティング付きガラス物品
CN107802642B (zh) * 2017-12-08 2020-07-24 惠觅宙 一种含有铝碳酸镁的药物组合物及制药用途
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP4342534A2 (en) 2018-03-08 2024-03-27 AM-Pharma B.V. Recombinant alkaline phosphatase for use in treating sepsis-associated acute kidney injury
CA3094173A1 (en) * 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
US20210189358A1 (en) * 2018-06-18 2021-06-24 Synthetic Biologics, Inc. Methods of making alkaline phosphatase agents
GB2599573A (en) 2019-05-31 2022-04-06 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
JP2022535401A (ja) * 2019-06-03 2022-08-08 シンセティック・バイオロジクス・インコーポレイテッド アルカリホスファターゼ製剤及びその使用
CN114891765B (zh) * 2019-11-21 2023-12-19 天津科技大学 一种磷脂酶及其应用
IL293616A (en) * 2019-12-09 2022-08-01 Alexion Pharma Inc Alkaline phosphatase polypeptides and methods of using them
WO2022055350A1 (en) 2020-09-09 2022-03-17 Am-Pharma B.V. Recombinant alkaline phosphatase for use in treating acute respiratory distress syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441252B1 (en) 1990-02-07 1997-09-03 Abbott Laboratories Alkaline phosphatase enzymes having improved specific activity for use in indicator reagents
AU4835693A (en) 1993-08-13 1995-03-14 Rijksuniversiteit Te Groningen Pharmaceutical composition comprising phosphatase or a derivative thereof
FR2736065B1 (fr) * 1995-06-29 1997-09-19 Commissariat Energie Atomique Phosphatases alcalines bacteriennes modifiees et leurs applications.
JP2000350596A (ja) * 1999-06-11 2000-12-19 Toyobo Co Ltd 分泌性アルカリフォスファターゼの選択的活性測定方法
JP2005065564A (ja) * 2003-08-22 2005-03-17 Hiroshi Ueda センサー蛋白質
US20110142817A1 (en) 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
CN1917899B (zh) 2004-02-04 2013-04-17 塞浦西斯阿瓦药物集团 碱性磷酸酶对存在于粘膜屏障的脂多糖解毒的用途
CA2599577A1 (en) * 2005-03-04 2006-09-14 Verenium Corporation Nucleic acids and proteins and methods for making and using them
US20070059300A1 (en) 2005-09-12 2007-03-15 Zoltan Laboratories Llc Compounds and compositions to control abnormal cell growth
EP1952823A1 (en) * 2007-01-30 2008-08-06 AM-Pharma B.V. The use of alkaline phosphatase in the treatment of reduced renal function
EP1985697A1 (en) 2007-04-27 2008-10-29 AM-Pharma B.V. Modified phosphatases

Also Published As

Publication number Publication date
NO2155866T3 (da) 2018-04-28
JP2010524496A (ja) 2010-07-22
EP1985697A1 (en) 2008-10-29
EP2666853A1 (en) 2013-11-27
EP2155866A2 (en) 2010-02-24
US20100143323A1 (en) 2010-06-10
SI2155866T1 (en) 2018-03-30
JP5320387B2 (ja) 2013-10-23
AU2008244716B2 (en) 2013-07-11
US20160046913A1 (en) 2016-02-18
US20140193388A1 (en) 2014-07-10
EP2155866B1 (en) 2017-11-29
CA2685405A1 (en) 2008-11-06
PL2155866T3 (pl) 2018-04-30
US8557545B2 (en) 2013-10-15
HUE036318T2 (hu) 2018-07-30
WO2008133511A3 (en) 2009-03-12
CA2685405C (en) 2016-12-13
ES2656405T3 (es) 2018-02-27
WO2008133511A2 (en) 2008-11-06
AU2008244716A1 (en) 2008-11-06
EP3336182A3 (en) 2018-09-19
EP3336182A2 (en) 2018-06-20
CN101688193A (zh) 2010-03-31
CN101688193B (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
DK2155866T3 (da) Modificerede phosphataser
WO2008036765A3 (en) Micrornas differentially expressed in pancreatic diseases and uses thereof
BRPI0715243A2 (pt) "método de aumento da produção de etanol e linhagem de z. mobilis"
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
NO20092652L (no) Konstruert anti-TSLP-antistoff
CY1113882T1 (el) Φαρμακευτικες συνθεσεις κυκλοσπορινης (cyclosporin)
DE602007006250D1 (de) Herstellung von vollkornhaltigen zusammengesetzten Nahrungsprodukten
DE602007007146D1 (de) Verfahren zur Herstellung von Müsliriegeln mit verbesserter Konsistenz
WO2006096490A8 (en) ANTI-MAdCAM ANTIBODY COMPOSITIONS
BRPI0716443A2 (pt) fibra, mÉtodo para fabricar uma fibra, e, produto de fibra
WO2007098270A3 (en) Co-crystals comprising vx-950 and pharmaceutical compositions comprising the same
EA201001639A1 (ru) Композиции и способы их получения и применения
ATE441638T1 (de) 4,5-diphenyl-pyrimidinyl substituierte carbonsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CR10523A (es) Cepa bg1 de thermoanaerobacter mathranii
DK2054502T3 (da) Nykonstrueret mikroorganisme, der producerer homo-ravsyre, og fremgangsmåde til fremstilling af ravsyre ved anvendelse af samme
BRPI0719398A2 (pt) Composição farmacêutica.
EA201101643A1 (ru) ВАРИАНТЫ ПРИМЕНЕНИЯ IL-1β АНТИТЕЛ И ИХ СВЯЗЫВАЮЩИХ ФРАГМЕНТОВ В СЕРДЕЧНО-СОСУДИСТОЙ СИСТЕМЕ
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
ATE517092T1 (de) Tetrahydronaphthalinderivate, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmer
WO2009115252A3 (de) Substituierte pyrazolamide und ihre verwendung
BRPI0718565A2 (pt) Forma de dosagem sólida, e, método de produção de uma forma de dosagem sólida.
BRPI0719529A2 (pt) Método para produzir uma preparação sólida, e, preparação sólida.
NO20070187L (no) Oralt desintegrerende farmasoytisk preparat omfattende risperidon
DE112007003101A5 (de) Telemedizinsystem, insbesondere für chronische Erkrankungen